Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Safety

Impact of Treatment-Related Cardiac Toxicity on Lymphoma Survivors: An Institutional Approach for Risk Reduction and Management

Michele C. Walsh
CJON 2010, 14(4), 505-507 DOI: 10.1188/10.CJON.505-507

Despite improvements in treatment and overall survival rates, survivors of lymphoma may have long-term and late effects. Given the immense risk for cardiac disease after treatment for Hodgkin lymphoma and non-Hodgkin lymphoma, healthcare providers should focus on prevention of secondary adverse effects. The Dana-Farber Cancer Institute has been working to develop guidelines to address the cardiotoxicities that impact the lymphoma survivor population.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or